S. 2164 117th Congress
Lower Costs, More Cures Act of 2021
Latest action, Jun 22, 2021: Read twice and referred to the Committee on Finance.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
8 cosponsors
Sponsored by Mike Crapo (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
0 D · 8 R
- Democrat
- Republican
- Independent
Referred to: Senate: Finance Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
7 reports
7 reports
BIOMARIN PHARMACEUTICAL INC.
CHAMBER HILL STRATEGIES
7 reports
7 reports
7 reports
7 reports
7 reports
7 reports
AMGEN USA INC.
MARSHALL & POPP, LLC
6 reports
AVANIR PHARMACEUTICALS
6 reports
EMD SERONO, INC.
THE D MAJOR GROUP
6 reports
All 25 of 46 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ABBVIE INC. | 7 | $12.1M | Q4 2021 | Q3 2022 | yes | |
| BAXTER HEALTHCARE CORPORATION | 7 | $3.4M | Q4 2021 | Q3 2022 | yes | |
| BIOMARIN PHARMACEUTICAL INC. | CHAMBER HILL STRATEGIES | 7 | $0 | Q4 2021 | Q3 2022 | yes |
| BIOMARIN PHARMACEUTICAL INC. | 7 | $2.0M | Q4 2021 | Q3 2022 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 7 | $23.5M | Q4 2021 | Q3 2022 | yes | |
| CAMBIA HEALTH SOLUTIONS | 7 | $3.3M | Q4 2021 | Q3 2022 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.0M | Q4 2021 | Q3 2022 | yes | |
| KAISER FOUNDATION HEALTH PLAN INC | 7 | $8.9M | Q4 2021 | Q3 2022 | yes | |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 7 | $6.1M | Q4 2021 | Q3 2022 | yes | |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | 7 | $357K | Q4 2021 | Q3 2022 | yes | |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 7 | $14.1M | Q4 2021 | Q3 2022 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | $49.3M | Q4 2021 | Q3 2022 | yes | |
| AMGEN USA INC. | MARSHALL & POPP, LLC | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| AVANIR PHARMACEUTICALS | 6 | $410K | Q4 2021 | Q3 2022 | yes | |
| EMD SERONO, INC. | THE D MAJOR GROUP | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| EXELIXIS, INC. | ARNOLD & PORTER KAYE SCHOLER LLP | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| GENENTECH, INC. | MARSHALL & POPP, LLC | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| HUMANA INC | 6 | $7.4M | Q4 2021 | Q3 2022 | yes | |
| PFIZER, INC. | MARSHALL & POPP, LLC | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | MARSHALL & POPP, LLC | 6 | $0 | Q4 2021 | Q3 2022 | yes |
| PRIME THERAPEUTICS | 6 | $490K | Q4 2021 | Q3 2022 | yes | |
| SANOFI U.S. SERVICES, INC. | MARSHALL & POPP, LLC | 6 | $360K | Q4 2021 | Q3 2022 | yes |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 5 | $13.1M | Q4 2021 | Q3 2022 | yes | |
| VERTEX PHARMACEUTICALS INCORPORATED | 5 | $2.5M | Q4 2021 | Q2 2022 | yes | |
| LUNDBECK LLC | 4 | $620K | Q4 2021 | Q1 2022 | yes |